
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics is a promising biopharmaceutical company with a strong product candidate in a new and potentially lucrative market. Their current valuation and risks are well managed, with a solid financial outlook that includes a 13% discount rate and 1% terminal growth rate. Their expected approval chances for their top three indications, as well as their FDA alignment, provide further confidence in their potential success. However, risks such as lack of durable responses and long-term dilution could potentially impact the company's future success.
Bears say
Kyverna Therapeutics is a clinical-stage biopharmaceutical company that has a negative outlook due to its limited product pipeline, high development costs, and competitive market for autoimmune therapies. Despite its successful clinical trials for SPS and gMG, the company may struggle to gain market share and generate significant revenues due to the smaller size of its potential patient populations and the presence of established competitors with similar treatments. Additionally, the company has yet to receive FDA approval for any of its products, and its financial statements show minimal revenues and high operating costs, raising concerns about its ability to sustain operations and continue development.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares